An Update on Current Usage of SGLT2-Inhibitors in Diabetic Kidney Disease: Special Focus on Dapagliflozin
Deodatta S. Chafekar
Supreme Kidney Care, Nashik, India.
Pinaki Mukherjee
Department of Nephrology, Nilratan Sircar Medical College, Kolkata, India.
K. N. Arun
Department of Nephrology and Renal Transplantation, Bhagwan Mahaveer Jain Hospital, Bangalore, India.
Manish Malik
Department of Nephrology, Institute of Renal Sciences, Sir Ganga Ram Hospital, New Delhi, India.
Biswajit Aich *
Medical Services, Zydus Healthcare Ltd., Goregaon (E), Mumbai, India.
Sameer K. Muchhala
Medical Services, Zydus Healthcare Ltd., Goregaon (E), Mumbai, India.
*Author to whom correspondence should be addressed.
Abstract
Diabetic Kidney Disease (DKD) is one of the most serious long-term outcomes in patients with T2DM. Prevalence of DKD is predicted to increase as the prevalence of diabetes is growing rapidly thereby leading to substantial morbidity and mortality. Established therapies still focus on effective glycemic control and blood pressure control, to arrest disease progression and regression of albuminuria. SGLT2 Inhibitors are a novel class of oral hypoglycaemic agents that increase urinary glucose excretion by suppressing glucose reabsorption at the renal proximal tubule. SGLT2 inhibitors lower HbA1c and improve various metabolic parameters including BP, lipid profile, albuminuria and uric acid. Clinical trials have shown that SGLT2 inhibitors improve cardiovascular and renal outcomes and mortality in patients with T2DM, thereby garnered considerable attention in the recent past and are considered potential first‑line candidates for the management of T2DM and has emerged as a cardio-renal game-changer.
Keywords: Diabetic kidney disease, sodium glucose co-transporters 2 inhibitors, dapagliflozin
How to Cite
Downloads
References
Diabetesatlas.org. IDF Diabetes Atlas 2021 | IDF Diabetes Atlas; 2022. [online]
Available:https://diabetesatlas.org/atlas/tenth-edition/
Access on 1 September 2022.
Tandon N, et al. India State-Level Disease Burden Initiative Diabetes Collaborators. Lancet Glob Health. 2018;6(12):e1352-e1362.
Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Journal of the American Society of Nephrology. 2005; 16(2):489-95.
Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. Journal of the American Society of Nephrology. 2013;24(2):302-8.
Varughese S, Abraham G. “Chronic kidney disease in India: A clarion call for change.” Clinical Journal of the American Society of Nephrology. 2018;13(5):802–804.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clinical journal of the American Society of Nephrology. 2017; 12(12):2032-45.
De Boer I, Khunti K, Sadusky T. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International; 2022.
DOI. 10.1016/j.kint.2022.08.012
Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes. Diabetes Care. 2022;44:S175-S184.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with kidney disease due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and kidney disease. N. Engl. J. Med. 2001;345:861–869.
Cheung AK, et al. Summary of KDIGO guideline on BP management in CKD. Kidney International. 2021;99:559–569
Baruah M, Makkar B, Ghatnatti V. Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control. Indian Journal of Endocrinology and Metabolism. 2019; 23(1):140.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 2017;377:644–657.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2019;380:347–357.
Wanner C, et al. EMPA-REG outcome: The nephrologist’s point of view. Am. J. Med. 2017;130:S63–S72.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383:1436–1446.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and KIDNEY disease. N. Engl. J. Med. 2019;380:2295–2306.
Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine; 2022.
Available:https://doi.org/10.1056/nejmoa2204233
Farxiga® (DAPAGLIFLOZIN) prescribing information | AZ medical information.
Available:https://medicalinformation.astrazeneca-us.com/home/prescribing-information/farxiga-pi.html
Access on Nov 3, 2022
McMurray JJV, Solomon SD, Inzucchi SE. “Dapagliflozin in patients with heart failure and reduced ejection fraction.” New England Journal of Medicine. 2019; 381(21):1995–2008.
Jongs N, et. al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755-766.
Heerspink HJL et. al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743-754.
Heerspink H, Cherney D, Postmus D, Stefánsson B, Chertow G, Dwyer J. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International. 2022; 101(1):174-184.
Persson, et. al. Efficacy and safety of dapagliflozin by baseline glycemic status: A prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021;44:1894–1897.
Persson F, Rossing P, Jongs N, et al. Efficacy of dapagliflozin by baseline diabetes medications: A prespecified analysis from the DAPA-CKD study. Diabetes 2022;71:866.
Rossing P, Inzucchi S, Vart P, Jongs N, Docherty K, Jhund. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: Pooled analysis of the DAPA-CKD and DAPA-HF trials. The Lancet Diabetes & Endocrinology. 2022;10(1):24-34.
Blonde L, Umpierrez G, Reddy S. American association of clinical endocrinology clinical practice guideline: Developing a diabetes mellitus comprehensive care plan update. Endocrine Practice. 2022;28(10):923-1049.
Hussain S, Habib A, Najmi AK. Int J Environ Res Publ Health. 2019;16(8):1443.